# **1157** - SIGNIFICANCE OF *TP53* ABERRATIONS IN CONTEXT OF OTHER PATHOGENIC SEQUENCE VARIANTS IN PATIENTS WITH **CHRONIC LYMPHOCYTIC LEUKEMIA IN THE ERA OF TARGETED THERAPY**

Zuzana Kubová<sup>\*1)</sup>, Veronika Kašková<sup>\*2)</sup>, Anna Petráčková<sup>2)</sup>, Peter Turcsányi<sup>1)</sup>, Jiřina Maňáková<sup>2)</sup>, Jakub Savara<sup>3)</sup>, Vít Doleží<sup>3)</sup>, Petr Gajdoš<sup>3)</sup>, Tomáš Papajík<sup>1)</sup>, Eva Kriegová<sup>2)</sup>

<sup>1)</sup>Hemato – oncology Dept., University Hospital Olomouc, Czech Republic <sup>2)</sup>Immunology Dept., Faculty of Medicine, Palacký University and University Hospital Olomouc, Czech Republic <sup>3)</sup>Faculty of Electrical Engineering and Computer Science, Technical University of Ostrava, Czech Republic \*Kubová, Kašková contributed equally

### **BACKROUND**:

Significant progress has been made in the treatment of chronic lymphocytic leukemia (CLL) over the past few decades. Targeted therapy replaced chemoimunotherapy in most patients. Improvement of progression-free survival (PFS) Bruton tyrosine kinase inhibitors (BTKi)based therapy in patients with TP53 disrupted CLL has been proven.

### AIM:

Analysis of the prognostic value of both isolated TP53 aberrations and • Median PFS was not reached in these patients compared to 40 in combination with other CLL associated pathogenic sequence variants months in patients with TP53 disruption. (PSV) in the cohort of BTKi-treated CLL patients.

### **METHODS**:

• ANALYSIS OF A SET OF 83 BTKi TREATED CLL PATIENTS, BETWEEN YEARS 2014 - 2022 AT HEMATO-ONCOLOGY DEPARTMENT UNIVERSITY HOSPITAL IN OLOMOUC

BTKI PATIENTS	N = 83 (49 %)	
SEX	Men	N = 49 (59 %)
	Female	N = 34 (41 %)
MEDIAN AGE	67 years (46 – 85)	
PRIOR	Naive	N = 6 (7 %)
TREATMENT	Pretreated	N = 77 (93%)
	4 and more lines	N = 11 (13%)
TYPE OF BTKi	Ibrutinib	N = 73 (88 %)
	2 <sup>nd</sup> generation BTKi	N = 10 (12%)

### **METHODS**:


### • EVALUATION OF:


- TP53 MUTATIONS BY NEXT- GENERATION SEQUENCING (NGS)
- 17p DELETIONS BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
- OTHER PSV BY BOTH NGS AND FISH ACCORDING TO TYPE


### • ANALYSIS OF:

- COMPARISON TP53wt (without mutation and/or 17p) deletion) VERSUS TP53 ABERRATED (with mutation and/or deletion of 17p) PATIENTS
- SIGNIFICANCE OF INDIVIDUAL TYPE OF *TP53* ABERRATIONS
- PFS EFFECT OF OTHER CLL ASSOCIATED PSV ALONE AND IN COMBINATION WITH TP53 DISRUPTION

## • Significant effect of biallelic aberration compared to *TP53wt* patients was demonstrated (p = 0.012), while in *TP53* mutated patients this trend was only indicated (p = 0.086).








	wt <i>TP53</i>	<i>TP53</i> MUT	DEL (17p)	BIALLELIC TP53
NO PTS.	45	20	4	14
MEDIAN PFS	NOT REACHED (NR)	40	39	40

Supported by grant IGA\_LF\_2023\_005, IGA\_LF\_2023\_010, MH\_CZ-DRO (FNOL, 00098892)

### **ISOLATED ABERRATION WITHOUT** *TP53* **DISRUPTION DOES NOT SHORTEN SURVIVAL**




months

Log-rank (Mantel-Cox) test Chi squqre P value		0.02687 <b>0.8698</b>
Median survival		
NOTCH1 without TP53	NR	
no NOTCH1 no TP53	NR	
No. patients		
NOTCH1 without TP53	14	
no NOTCH1 no TP53	37	

Log-rank (Mantel-Cox) test Chi square P value	2.324 <b>0.1274</b>
Median survival	
ATM without TP53	NR
no ATM no <i>TP53</i>	NR
No. patients	
ATM without TP53	23
no ATM no <i>TP53</i>	21
Log ronk (Mantal Cav) tost	
Log-rank (Mantel-Cox) test Chi square <u>P value</u>	0.06481 <b>0.7990</b>
Median survival	
SF3B1 without TP53	NR
no SF3B1 no <i>TP53</i>	NR
No. patients	
SF3B1 without TP53	10

41

no SF3B1 no TP53





### *TP53* DISRUPTION IN COMBINATION WITH OTHER CHANGES SIGNIFICANTLY SHORTENS SURVIVAL

253 vs. no NOTCH1 no SF3B1 no TP53	Log-rank (Mantel-Cox) test Chi squqre P value		5.345 <b>0.0208</b>
no NOTCH1 no SF3B1 no TP53			
NOTCH1 with <i>TP53</i>	Median survival		
	NOTCH1 with TP53	25	
	no NOTCH1 no SF3B1 no TP53	NR	
	No. patients		
40 60 80	NOTCH1 with TP53	8	
months	no NOTCH1 no SF3B1 no TP53	28	
rs. no ATM no SF3B1 no <i>TP53</i>	Log-rank (Mantel-Cox) test Chi squqre P value		10.07 <b>0.0018</b>
no ATM no SF3B1 no TP53			
ATM with <i>TP53</i>	Median survival		
	ATM with TP53	20	
	no ATM no SF3B1 no TP53	NR	
	No. patients		
40 60 80	ATM with TP53	11	
months	no ATM no SF3B1 no TP53	21	
3 vs. no SF3B1 no <i>TP53</i>	Log-rank (Mantel-Cox) test Chi squqre P value		11.29 <b>0.0009</b>
no SF3B1 no <i>TP53</i>	Median survival		
	SF3B1 with TP53	40	
	no SF3B1 no <i>TP53</i>	NR	
u ا	No. patients		
) 40 60 80	SF3B1 with TP53	13	
months	no SF3B1 no TP53	41	

### *TP53* DISRUPTION ONLY VERSUS NO CHANGES – **NO SIGNIFICANT DIFFERENCE IN PFS**

PFS impact of combination of other variants (NOTCH1 p=0.021, ATM p=0.002, SF3B1 p=0.009) in presence of TP53 was confirmed compared to no PSV together with *wtTP53*.

To support results that TP53 disruption has impact only in combination of other PSV, we analyzed subgroup of patients with isolated TP53

disruption without any other common change in comparison to patients with no changes at all and we found that the difference of PFS between these two groups did not reach significance (p = 0.312).

<i>TP53</i> disruption (mut or/and del(17p)) vs. no NOTCH1 no SF3B1 no <i>TP53 no ATM</i>		Log-rank (Mantel-Cox) test Chi squqre P value		1.02 <b>0.312</b>
100 - no NOTCH1 no SF3B1	no <i>TP53 no ATM</i>			
TP53 disruption (mut of	pr/and del(17p))	Median survival		
		TP53 disruption (mut or/and del(17p))	NR	
TP53 disruption (mut or/and de		no NOTCH1 no SF3B1 no TP53 no ATM	50.5	
		No. patients		
$0 \frac{1}{1} $		TP53 disruption (mut or/and del(17p))	12	
0 20 40 60 80 months				
	NE VS	no NOTCH1 no SF3B1 no TP53 no ATM	12 ED IN	
TP53 DISRUPTED ALO COMBINATION WITH C		S. <i>TP53</i> DISRUPTI SPSV VS. NO CH/	ED IN ANGE	
P53 DISRUPTED ALO		5. <i>TP53</i> DISRUPTI PSV VS. NO CH/	ED IN ANGE months	P VALUE
<b>P53 DISRUPTED ALO</b> <b>COMBINATION WITH C</b> <b>KOMBINACE</b>	DTHER	S. <i>TP53</i> DISRUPTI SPSV VS. NO CH/	ED IN ANGE	
<b>EXAMPLE 100</b>	DTHER ut or/and del(17p)) TCH1/SF3B1/ATM)	5. TP53 DISRUPTI PSV VS. NO CH/ MEDIAN SURVIVAL TP53 disruption alone (mut or/and	ED IN ANGE months	P VALUE
<b>EXAMPLE 100</b>	DTHER ut or/and del(17p)) TCH1/SF3B1/ATM)	<b>5.</b> TP53 DISRUPTI PSV VS. NO CH/ MEDIAN SURVIVAL TP53 disruption alone (mut or/and del(17p))	ED IN ANGE MONTHS NR	P VALUE
<b>EXAMPLE 100</b>	DTHER ut or/and del(17p)) TCH1/SF3B1/ATM)	<b>S. TP53 DISRUPT</b> <b>PSV VS. NOCH</b> <b>MEDIAN SURVIVAL</b> <i>TP53</i> disruption alone (mut or/and del(17p)) no NOTCH1 no SF3B1 no <i>TP53 no ATM</i>	EDINACUUE MONTHS NR 50.5	<b>P VALUE</b> 0.312

### **CONCLUSION:**

DESPITE IMPROVEMENT OF SURVIVAL IN OUR BTKI TREATED COHORT, NEGATIVE PROGNOSTIC VALUE OF TP53 ABERRATION, STILL REMAINED PRESERVED. HOWEVER, THERE IS A NEED TO EVALUATED THE SIGNIFICANCE IN THE CONTEXT OF OTHER CLL ASSOCIATED PATHOGENIC SEQUENCE VARIANTS.